UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 510

Sortiert nach

2016 WHO Classification update—What's new in lymphoid neoplasms

International journal of laboratory hematology, 2017-05, Vol.39 (S1), p.14-22

Hsi, E. D.

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

Annals of oncology, 2012-09, Vol.23 (9), p.2356-2362

2012

Link zum Volltext

Verfügbarkeit prüfen

Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study

The journal of clinical endocrinology and metabolism, 1996-05, Vol.81 (5), p.1736-1739

Hsi, E. D.

1996

Link zum Volltext

Verfügbarkeit prüfen

Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism

Annals of oncology, 2010-11, Vol.21 (11), p.2246-2254

2010

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

Annals of oncology, 2017-11, Vol.28 (11), p.2806-2812

2017

Link zum Volltext

Verfügbarkeit prüfen

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

Cell death & disease, 2015-01, Vol.6 (1), p.e1593-e1593

2015

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study

Annals of oncology, 2010-06, Vol.21 (6), p.1196-1202

2010

Link zum Volltext

Verfügbarkeit prüfen

UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation

Leukemia, 2009-03, Vol.23 (3), p.610-614

2009

Link zum Volltext

Verfügbarkeit prüfen

PRPF8 defects cause missplicing in myeloid malignancies

Leukemia, 2015-01, Vol.29 (1), p.126-136

2015

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal antibodies against IREM-1: potential for targeted therapy of AML

Leukemia, 2009-09, Vol.23 (9), p.1587-1597

2009

Link zum Volltext

Verfügbarkeit prüfen

Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen

Bone marrow transplantation (Basingstoke), 2007-08, Vol.40 (3), p.239-243

2007

Link zum Volltext

Verfügbarkeit prüfen

Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909

Haematologica (Roma), 2012-04, Vol.97 (4), p.579-585

2012

Link zum Volltext

Verfügbarkeit prüfen

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy

Leukemia, 2018-02, Vol.32 (2), p.353-363

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

Haematologica (Roma), 2010-01, Vol.95 (1), p.71-78

2010

Link zum Volltext

Verfügbarkeit prüfen

Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium

Leukemia, 2016-02, Vol.30 (2), p.361-372

2016

Link zum Volltext

Verfügbarkeit prüfen

Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma

Leukemia, 2015-09, Vol.29 (9), p.1857-1867

2015

Link zum Volltext

Verfügbarkeit prüfen

Primary Cutaneous Follicular Lymphoma: An Assessment of Clinical, Histopathologic, Immunophenotypic, and Molecular Features

Journal of clinical oncology, 2002-02, Vol.20 (3), p.647-655

Mirza, I.

2002

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

Annals of oncology, 2018-11, Vol.29 (11), p.2271-2271

2018

Link zum Volltext

Verfügbarkeit prüfen

A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma

Histopathology, 2000-07, Vol.37 (1), p.10-18

2000

Link zum Volltext

Verfügbarkeit prüfen

Posttransplant Lymphoproliferative Disorders in Lung Transplant Patients: The Cleveland Clinic Experience

Modern pathology, 2002-06, Vol.15 (6), p.647-656

2002

Link zum Volltext

Verfügbarkeit prüfen

Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients

The American journal of surgical pathology, 2000, Vol.24 (1), p.100-106

2000

Link zum Volltext

Verfügbarkeit prüfen

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

Leukemia, 2017-03, Vol.31 (3), p.625-636

2017

Link zum Volltext

Verfügbarkeit prüfen

CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL)

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Link zum Volltext

Verfügbarkeit prüfen

A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratory

Archives of pathology & laboratory medicine (1976), 2001-02, Vol.125 (2), p.289-294

Hsi, E D

2001

Link zum Volltext

Verfügbarkeit prüfen

Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma

Leukemia, 2005-05, Vol.19 (5), p.856-861

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 510

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(467)
Mit Volltextzugriff
(466)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(357)
Life Sciences & Biomedicine
(285)
Humans
(263)
Female
(125)
Male
(123)
Biological And Medical Sciences
(110)
Middle Aged
(106)
Medical Sciences
(98)
Adult
(96)
Pathology
(89)
Aged
(86)
Hematology
(59)
Immunohistochemistry
(57)
Physical Sciences
(55)
Hematologic And Hematopoietic Diseases
(50)
Oncology
(50)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(48)
Animals
(47)
Aged, 80 And Over
(44)
Lymphoma
(43)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

2016 WHO Classification update—What's new in lymphoid neoplasms

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study

Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study

UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation

PRPF8 defects cause missplicing in myeloid malignancies

Monoclonal antibodies against IREM-1: potential for targeted therapy of AML

Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen

Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium

Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma

Primary Cutaneous Follicular Lymphoma: An Assessment of Clinical, Histopathologic, Immunophenotypic, and Molecular Features

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma

Posttransplant Lymphoproliferative Disorders in Lung Transplant Patients: The Cleveland Clinic Experience

Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL)

A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratory

Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma

Suchergebnisse filtern